DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02094833 |
Recruitment Status :
Completed
First Posted : March 24, 2014
Last Update Posted : April 26, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The aim of this study is to evaluate the immunogenicity and safety of a novel DTaP-IPV-Hep B-PRP~T fully liquid combined hexavalent vaccine (study vaccine) administered at 2, 4, and 6 months of age compared to Sanofi Pasteur's DTaP-IPV//PRP~T combined vaccine (Pentaxim™) given at 2, 4, and 6 months of age and Hep B vaccine (Euvax B®) given at 1 and 6 months of age in South Korean infants that received a birth dose of Hep B and born to mothers documented to be serum anti-HBs Ag negative.
Primary Objective
- To demonstrate the non-inferiority in terms of seroprotection (Diphtheria, Tetanus, poliovirus types 1, 2, and 3, PRP-T, Hep B) and vaccine response for pertussis antigens (pertussis toxoid [PT] and filamentous haemagglutinin [FHA]) of Group A versus Group B, one month after the third dose of combined vaccines.
Secondary Objectives:
- To further study the immunogenicity of the two vaccination schemes, before the first dose and one month after the last dose of vaccines.
- To study the safety after each and any dose of vaccines administered in the two vaccination schemes
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diphtheria Tetanus Pertussis Haemophilus Influenzae Type b Infection Poliomyelitis Hepatitis B | Biological: DTaP-IPV-Hep B-PRP~T combined vaccine Biological: DTaP-IPV//PRP~T and Hepatitis B vaccine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 310 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Immunogenicity and Safety of Sanofi Pasteur's DTaP-IPV-Hep B-PRP~T Combined Vaccine at 2, 4, and 6 Months of Age Versus Sanofi Pasteur's DTaP IPV//PRP~T Combined Vaccine at 2, 4, and 6 Months of Age + Hep B Vaccine at 1 and 6 Months of Age, in South Korean Infants Primed With Hep B at Birth |
Actual Study Start Date : | March 2014 |
Actual Primary Completion Date : | April 2016 |
Actual Study Completion Date : | November 2016 |

Arm | Intervention/treatment |
---|---|
Experimental: Group A
Participants will receive 3 injections of the study vaccine (DTaP-IPV-Hep B-PRP~T combined vaccine) at 2, 4, and 6 months of age
|
Biological: DTaP-IPV-Hep B-PRP~T combined vaccine
0.5 mL, Intramuscular |
Active Comparator: Group B
Participants will receive 2 injections of monovalent Hep B vaccine (Euvax B®) at age 1 and 6 months and 3 injections of DTaP IPV//PRP~T vaccine (Pentaxim™) at age 2, 4, and 6 months
|
Biological: DTaP-IPV//PRP~T and Hepatitis B vaccine
0.5 mL, Intramuscular
Other Names:
|
- Number of participants with anti-Diphtheria antibody concentrations ≥ 0.01 International Units (IU)/mL [ Time Frame: 1 month post third vaccination ]Anti-Diphtheria antibodies will be measured by a toxin neutralization test
- Number of participants with anti-Tetanus antibody concentrations ≥ 0.1 International unit (IU)/mL [ Time Frame: 1 month post third vaccination ]Anti-Tetanus antibodies will be measured by enzyme-linked immunosorbent assay (ELISA).
- Number of participants with ≥ 4 fold increase in anti-PT and anti-FHA antibody concentrations (EU/mL) from 1 month pre-dose 1 to 1 month post-dose 3 [ Time Frame: I month post dose 3 ]Anti-PT and anti-FHA antibodies will be measured by enzyme-linked immunosorbent assay (ELISA).
- Number of participants with anti-Diphtheria antibody concentrations ≥ 0.01 IU/mL and ≥ 0.1 IU/mL International Units (IU)/mL [ Time Frame: Day 0 Pre-vaccination ]Anti-Diphtheria antibodies will be measured by a toxin neutralization test
- Number of participants with anti-Hepatitis B antibody concentrations ≥ 10 mIU/mL international unit (IU)/mL [ Time Frame: Day 0 Pre-vaccination ]Anti-Hepatitis B antibodies will be measured by the commercially available VITROS ECi/ECiQ Immunodiagnostic System using chemiluminescence detection technology
- Number of participants with anti Diphtheria antibody concentrations ≥ 0.1 IU/mL International Units (IU)/mL [ Time Frame: 1 month post third vaccination ]Anti-Diphtheria antibodies will be measured by a toxin neutralization test
- Number of participants reporting solicited injection site and solicited systemic reactions, unsolicited adverse events, and serious adverse events following vaccination with either DTaP-IPV-Hep B-PRP~T combined vaccine or Pentaxim™ and Euvax B® vaccine [ Time Frame: Day 0 and up to Day 180 post-vaccination ]Solicited injection site reactions Tenderness, Erythema, and Swelling. Solicited systemic reactions Fever (temperature), Vomiting, Crying abnormal, Drowsiness, Appetite loss, and Irritability.
- Number of participants with response to vaccine Pertussis toxoid (PT) and Filamentous Haemagglutinin (FHA) antigens [ Time Frame: 1 month post third vaccination ]Vaccine response defined as: Post-dose 3 anti-PT and anti-FHA antibody concentrations in ELISA units (EU)/mL ≥ 4 x Lower Limit of Quantitation (LLOQ) if pre-vaccination concentration is < 4 x LLOQ or ≥ pre-vaccination concentration if pre-vaccination concentrations ≥ 4 x LLOQ

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 1 Month to 6 Months (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Aged 30 to 40 days on the day of the first study visit
- Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg
- Informed consent form has been signed and dated by the parent(s) or other legally acceptable representative
- Participant and parent/legally acceptable representative are able to attend all scheduled visits and to comply with all trial procedures
- Born to known hepatitis B surface antigen (HBsAg) seronegative mother (documented laboratory result of HBsAg assay from the maternal blood sample is available)
- Have received one documented dose of Hep B vaccine at birth according to the national recommendations.
Exclusion Criteria:
- Participation in the 4 weeks preceding the trial inclusion or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
- Receipt of any vaccine in the 4 weeks preceding any trial vaccination (except Bacille Calmette Guerin (BCG) vaccine) or planned receipt of any vaccine in the 8 days following any trial vaccination
- Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B (except the dose of Hep B vaccine given at birth) diseases or Haemophilus influenzae type b infection with either the trial vaccine or another vaccine
- Past or current receipt of immune globulins, blood or blood-derived products or planned administration during the trial
- Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, since birth; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks since birth)
- Known personal or maternal history of Human Immunodeficiency Virus (HIV) or hepatitis C seropositivity
- History of diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, or Haemophilus influenzae type b infection, confirmed either clinically, serologically, or microbiologically
- Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
- Known thrombocytopenia, as reported by the parent/legally acceptable representative
- Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating intramuscular vaccination
- In an emergency setting, or hospitalized involuntarily
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
- Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided
- Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study
- History of seizures.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02094833
Korea, Republic of | |
Daejeon, Korea, Republic of, 301 724 | |
Gyeonggi do, Korea, Republic of, 425 707 | |
Gyeonggi Do, Korea, Republic of | |
Gyeongsangnam do, Korea, Republic of, 641 560 | |
Gyeongsangnam do, Korea, Republic of | |
Jeollabuk do, Korea, Republic of, 570 711 | |
Jeonbuk, Korea, Republic of, 561 712 | |
Kangwon do, Korea, Republic of, 220 701 | |
Kyunggi Do, Korea, Republic of, 420 717 | |
Seoul, Korea, Republic of, 120 752 | |
Seoul, Korea, Republic of, 130 87 | |
Seoul, Korea, Republic of, 137 701 | |
Seoul, Korea, Republic of, 139 709 | |
Seoul, Korea, Republic of, 158 710 | |
Seoul, Korea, Republic of | |
Suwon Gyeonggi do, Korea, Republic of, 442 723 |
Study Director: | Medical Director | Sanofi Pasteur SA |
Responsible Party: | Sanofi Pasteur, a Sanofi Company |
ClinicalTrials.gov Identifier: | NCT02094833 |
Other Study ID Numbers: |
A3L31 U1111-1127-6896 ( Other Identifier: WHO ) |
First Posted: | March 24, 2014 Key Record Dates |
Last Update Posted: | April 26, 2017 |
Last Verified: | April 2017 |
Diphtheria Tetanus Pertussis |
Haemophilus influenzae type b infection Hepatitis B DTaP-IPV-Hep - PRP-T vaccine |
Hepatitis B Whooping Cough Tetanus Diphtheria Poliomyelitis Haemophilus Infections Hepatitis Infections Liver Diseases Digestive System Diseases Hepatitis, Viral, Human Virus Diseases Enterovirus Infections Picornaviridae Infections RNA Virus Infections |
Respiratory Tract Infections Respiratory Tract Diseases Blood-Borne Infections Communicable Diseases Hepadnaviridae Infections DNA Virus Infections Bordetella Infections Gram-Negative Bacterial Infections Bacterial Infections Bacterial Infections and Mycoses Clostridium Infections Gram-Positive Bacterial Infections Nervous System Diseases Corynebacterium Infections Actinomycetales Infections |